1. Bering, B. and Müller, W. E., “Interaction of piracetam with several neurotransmitter receptors in the central nervous system,” Drug Res., 35, 1350–1352 (1985).
2. Boiko, S. S., Korotkov, S. A., Zherdev, V. P., et al., “Pharmacokinetics and BBB permeability of a novel acylprolinedipeptide with nootropic properties after oral administration,” Byull. Eksperim. Biol. Med., 129, No. 4, 426–429 (2000).
3. Bulatov, V. V., Khokhoev, T. Kh., Dikii, V. V., et al., “The problems of small and supersmall doses in toxicology. Basic and applied aspects,” Ros Khim. Zh., XLVI, No. 6, 58–62 (2002).
4. Calabrese, E. J., Iavicoli, I., and Calabrese, V., “Hormesis: its impact on medicine and health,” Hum. Exp. Toxicol., 32, No. 2, 120–52 (2013), doi: https://doi.org/10.1177/0960327112455069.
5. Collerton, F., “Cholinergic function and intellectual decline in Alzheimer’s disease,” Neuroscience, 19, l–28 (1986).